Abstract: The present disclosure relates to the technical field of biotechnology, and discloses a nucleic acid targeting angiotensinogen and uses thereof. The nucleic acid provided by the present disclosure can effectively inhibit the expression of AGT, thereby being capable of treating and/or preventing disease related to elevated AGT expression such as hypertension.

Abstract: The present disclosure relates to the technical field of biotechnology, and discloses a nucleic acid targeting proprotein convertase subtilisin/kexin 9 and uses thereof. The nucleic acid provided by the present disclosure can effectively inhibit the expression of PCSK9, thereby being capable of treating and/or preventing hyperlipidemia related diseases.

Abstract: The invention provides compounds, methods, and pharmaceutical compositions for reducing the amount or activity of N-acylsphingosine amidohydrolase (acid ceramidase) 1 (ASAH1) mRNA, and in certain embodiments reducing the amount of ASAH1 protein in a cell or animal, wherein reducing the amount or activity of ASAH1 would be beneficial.

Abstract: The invention provides compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Apolipoprotein E (ApoE) mRNA, and in certain embodiments reducing the amount of ApoE protein in a cell or animal, wherein reducing the amount or activity of ApoE would be beneficial.

Abstract: Hardware and neural architecture co-search may be performed by operations including obtaining a specification of a function and a plurality of hardware design parameters. The hardware design parameters include a memory capacity, a number of computational resources, a communication bandwidth, and a template configuration for performing neural architecture inference. The operations further include determining, for each neural architecture among a plurality of neural architectures, an overall latency of performance of inference of the neural architecture by an accelerator within the hardware design parameters. Each neural architecture having been trained to perform the function with an accuracy. The operations further include selecting, from among the plurality of neural architectures, a neural architecture based on the overall latency and the accuracy.

Abstract: Disclosed herein are compounds, compositions, and methods for decreasing TIGIT mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate TIGIT associated diseases, disorders, and conditions.

Abstract: Hardware and neural architecture co-search may be performed by operations including obtaining a specification of a function and a plurality of hardware design parameters. The hardware design parameters include a memory capacity, a number of computational resources, a communication bandwidth, and a template configuration for performing neural architecture inference. The operations further include determining, for each neural architecture among a plurality of neural architectures, an overall latency of performance of inference of the neural architecture by an accelerator within the hardware design parameters. Each neural architecture having been trained to perform the function with an accuracy. The operations further include selecting, from among the plurality of neural architectures, a neural architecture based on the overall latency and the accuracy.

Abstract: Disclosed herein are compounds, compositions, and methods for decreasing TIGIT mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate TIGIT associated diseases, disorders, and conditions.

Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating NLRP3 mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.

Abstract: The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.

Abstract: The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.

Abstract: The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.